Phase 1 N=30 Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1076.37; 1223.89 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=73 A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
Malignant Solid Tumor · Solid Tumor · Metastatic Tumor
Primary: Recommended Dose for Phase 2 Studies — 90 mg every other day for 21 days
Phase 1 N=47 A Study of LY2495655 in Healthy Subjects
Healthy Volunteer
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 7; 4 Participants
Phase 1 N=44 A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Neoplasms
Primary: Number of Participants With Adverse Events (AEs) — 6; 3; 3; 11 Participants
Phase 1 N=24 Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents
Healthy Subjects
Primary: Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of Guaifenesin — 1990; 1700; 4390; 3910 ng*hr/mL
Phase 1 N=27 An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Malignant Melanoma
Primary: Maximum Tolerated Dose (MTD) of IMC-20D7S — 20 mg/kg q2w
Phase 1 N=12 ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
Phase 1 N=60 Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
Phase 1 N=24 A Bioavailability Study of LY2452473 and Tadalafil
Erectile Dysfunction
Primary: Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY2452473 — 514; 495; 453; 463 nanograms*hours per milliliter (ng*h/mL)
Phase 1 N=32 Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 17; 9; 3; 1 Participants
Phase 1 N=33 IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose — 115 milligrams per meter squared
Phase 1 N=52 A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants
Healthy Participants
Primary: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Esomeprazole — 1908.0; 1922.2 hour*nanogram per milliliter (h*ng/mL)
Phase 1 N=25 Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Lung Cancer · Non-small Cell Lung Cancer (NSCLC)
Primary: Maximum Tolerated Dose (MTD) of Afatinib (BIBW 2992) in Combination With Dasatinib — 30; 100 mg
Phase 1 N=116 Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole — 515.7; 519.5; 1027.0; 978.6 nanogram/milliliter (ng/mL) — p=0.5535
Phase 1 N=45 A Study of LY2951742 in Healthy Japanese and Caucasian Participants
Migraine Disorders
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants